(a).
| Year | Study | System used to obtain PRP | Type of cells | Dose |
|---|---|---|---|---|
| 2006 | Akeda et al. [18] | SYMPHONY | Porcine IVD NP cell AF cell | 10% PRP, 10% PPP |
| 2006 | Chen et al. [19] | Centrifuged | hNP | PRP (defined as TGF-β1 equivalent) |
| 2009 | Chen et al. [20] | Centrifuged | Porcine IVD organ induced with chymopapain | 10% porcine PRP |
| 2013 | Mietsch et al. [32] | Centrifugation and double filtration | hNP MSC | 10% PRP MSC |
| 2014 | Kim et al. [28] | GPS III System | hNP | 5%, 10% PRP |
| 2014 | Liu et al. [29] | Not declared | ihNP | PRP (defined as TGF-β1 1 ng/ml equivalent) |
| 2014 | Pirvu et al. [21] | INTERCEPT Blood System | Bovine AF cells | 25%–50% human PRP 25%–50% human platelet lysate |
| 2016 | Yang et al. [22] | Centrifuged | Rabbit NP cells | 10%, 5%, 2.5%, and 1% volume fractions of PRP |
| 2016 | Cho et al. [30] | Centrifuged | Porcine AF cells with TNF-α | PRP of 1, 5, 10 × 107 platelets/ml |
| 2018 | Wang et al. [24] | Two-step centrifugation | Rabbit NP-derived stem cells | 5%–20% rabbit P-PRP or L-PRP |
| 2018 | Jia et al. [25] | Two-step centrifugation | NPMSCs | 10% P-PRP or 10% L-PRP |
| 2018 | Hondke et al. [33] | Not declared | hAF | PRP 5% |